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Summary The treatment of complicated intra-abdominal infections continues to
challenge physicians, primarily because of the polymicrobial nature of these infections
coupled with the high risk of complications and even death among the more severe
patients. The initial selection of antimicrobial therapy for treatment of nosocomial intra-
abdominal infections is extremely important because an association has been shown
between inappropriate empiric antimicrobial therapy and delayed clinical resolution,
increased length of hospital stay, and an increased risk of mortality. Moreover, it is becoming
more frequent for isolates recovered from patients to possess multiple resistance factors
(e.g., extended-spectrum b-lactamases [ESBLs], vancomycin-resistant enterococci [VRE]).
Therefore, when selecting empiric antimicrobial therapy, the physician must consider the
likelihood of encountering one of these difﬁcult-to-treat isolates and select an agent
or agents with anticipated activity against such organisms. Here, we discuss the merits
and limitations of empiric therapy for nosocomial intra-abdominal infections, review the
current guidelines for treatment, and discuss the therapeutic options currently available.
© 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.
Introduction
Nosocomial intra-abdominal infections are among the most
difﬁcult infections to diagnose early and treat effectively.
A successful outcome depends on early diagnosis, rapid
and appropriate surgical intervention, and the selection of
efﬁcacious antibiotic regimens 1. The delay of surgery has
been associated with a signiﬁcant increase in mortality 2,3.
Intra-abdominal infections occur when the normally
sterile abdominal cavity is invaded by bacterial ﬂora 1.
The leakage of the endogenous microﬂora into adjacent
tissues appears to overwhelm the host’s defense mecha-
nisms, resulting in infection. Nosocomial intra-abdominal
infections, deﬁned as those arising in a patient hospitalised
for more than 48 hours, are usually caused by hospital-
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acquired ﬂora, which may include organisms that have
acquired antibacterial resistance 4.
Bacterial peritonitis and intra-abdominal abscesses
are the most commonly encountered intra-abdominal
infections. They share a similar microbial etiology,
and, accordingly, are treated similarly with respect to
antibiotic therapy and the need for surgical intervention 5.
Peritonitis, deﬁned as inﬂammation of the peritoneum
due to a bacterial infection, can occur spontaneously;
however, secondary peritonitis is far more common.
Common causes of secondary bacterial peritonitis include
penetrating abdominal trauma, blunt trauma, appendicitis,
diverticulitis, gastroduodenal ulcus perforation, biliary
tract infections, and post-operative complications follow-
ing abdominal procedures 5. The level of contamination
of the peritoneum by bacteria and other gut contents
determines the extent of the inﬂammatory response
elicited. This response includes the release of humoral
inﬂammatory mediators, as well as the recruitment of
macrophages and polymorphonuclear leucocytes to the
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Table 1
Microbiology of intra-abdominal infections
Montravers (1996) 11
(%)
Dupont (2000) 12
(%)
Sotto (2002) 3
(%)
Roehrborn (2002) 13
(%)
Aerobes 85 80 82 80
Gram-negative bacilli 53 45 47 44
E. coli 21 24 23 19
Proteus spp. 10 3 – –
Klebsiella spp. 6 5 5 7
Enterobacter spp. 4 8 – 12
Pseudomonas spp. 8 5 5 6
Gram-positive cocci 32 35 35 36
Enterococcus spp. 17 21 19 21
Staphylococcus spp. 10 4 9 11
Streptococcus spp. 6 4 7 4
Anaerobes 6 14 11 7
Bacteroides spp. 5 7 – 7
Clostridium spp. 0.1 2 – –
Yeasts 9 6 7 4
site of contamination 6. If the level of contamination
is relatively low and the inﬂammatory response is able
to conﬁne the process to the immediate locality of
the contamination, an abscess results. If the level
of contamination is so high that the inﬂammatory
response is overwhelmed, peritonitis develops and surgical
intervention is required 7. Moreover, an immunosuppression
due to the ﬁrst surgical procedure has been described and
may limit host ﬁght during post-operative peritonitis 6,8,9.
Gastrointestinal microﬂora and the
etiology of intra-abdominal infections
A wide variety of microorganisms inhabit the gastroin-
testinal (GI) tract, and the numbers and types of these
organisms increase progressively down the GI tract. The
stomach and proximal small intestine of healthy individuals
support a somewhat sparse bacterial ﬂora that includes
both aerobes and anaerobes (<104/mL) 10. Acidity and
motility appear to be the major factors that inhibit the
growth of bacteria in the stomach.
The gastric microﬂora comprises primarily penicillin-
sensitive anaerobes and aerobic coliforms. The microﬂora
of the distal small bowel, however, represents a transi-
tional zone between the microﬂoras of the upper and lower
GI tracts. Here, aerobic and anaerobic microorganisms
are usually detected at concentrations between 103 and
108/mL. The highest concentrations of microorganisms are
found in the colon, where up to 108 aerobic coliforms and
1011 anaerobes per gram of stool or per mL of intestinal
aspirate have been detected 10.
The predominant aerobes involved in intra-abdominal
infections appear to include Escherichia coli, Klebsiella,
Streptococcus, Proteus, and Enterobacter species; the
anaerobes most frequently isolated are Bacteroides,
Peptostreptococcus, and Clostridium species. B. fragilis is
the single most often isolated anaerobe, accounting for
almost 40% of all anaerobe isolates (Table 1). However,
some modiﬁcations of the bacteria both quantitatively and
qualitatively are involved in post-operative infections. The
proportion of Gram-negative rods is the same in nosocomial
infections as in community-acquired infections, with a
predominance of E. coli and Enterobacteriaceae 3,12,11,13
(Table 1). However, a marked modiﬁcation in Gram-positive
cocci proportion is observed in nosocomial infections
when compared to community-acquired infection: the
ﬁrst population isolated are enterococci, followed by
staphylococci, while streptococci are the last.
In addition, highly antibiotic-resistant strains of or-
ganisms such as Pseudomonas aeruginosa, Serratia
marcescens, Acinetobacter and Providencia species are
frequently isolated from patients who develop nosocomial
sepsis. Persistent peritonitis in patients with long-term
hospitalisations, repeated courses of antibiotics, multiple
surgeries, and/or admissions to the intensive care unit
favor the growth of breakthrough microorganisms such
as Staphylococcus epidermidis as well as Enterococcus
and Candida species 14. In addition, the increasing
incidence of resistant pathogens (such as meticillin-
resistant Staphylococcus aureus (MRSA), vancomycin-
resistant enterococci (VRE), cephalosporinase-producing
Enterobacteriaceae, and extended-spectrum b-lactamase
[ESBL] producers) requires the selection of more intensive
therapeutic regimens for nosocomial infections. However,
Pseudomonas aeruginosa is not a real problem in intra-
abdominal infection because this bacterium is rarely
isolated 12. Therapy for these infections should be based
on common isolates found at the particular facility and on
local susceptibility patterns and surveillance data.
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Aldridge et al. 15 conducted a susceptibility study of
clinical anaerobic isolates from four large US medical cen-
tres and found that of the antibiotics tested piperacillin–
tazobactam was the only one to which all 556 isolates were
susceptible. Of particular concern in that study were the
resistance rates among the B. fragilis group to ampicillin-
sulbactam and clindamycin, which were 11% and 29%,
respectively.
The need for appropriate empiric therapy
All initial antibiotic therapy for intra-abdominal infections
is empiric because of the large number of potential
infecting organisms and the fact that culture and
susceptibility results can take 48 hours to become
available. The goal of empiric antibiotic therapy is to
deliver treatment to the patient as early as possible, and
then tailor therapy to match the infecting organism(s) once
laboratory results are known. Appropriate empiric therapy,
therefore, invariably requires the use of broad-spectrum
agents to achieve the necessary coverage for both common
and more unusual organisms. Prompt administration of
antibiotics is essential as studies have shown that antibiotic
administration later than 8 hours after hospitalisation
increases patient morbidity and mortality in both severe
community-acquired and severe nosocomial infections 16.
Inappropriate therapy must therefore be deﬁned as
the use of an antibiotic or antibiotics that was or
were unable to provide adequate coverage for the
bacterial pathogens subsequently identiﬁed by culture.
Additional factors may include delayed administration and
incorrect dosing 17. Another consideration is that increasing
antibiotic resistance is making many previously effective
antibiotic regimens inappropriate. Surveillance programs
designed to monitor the emergence of antimicrobial-
resistant pathogens have shown a consistent increase in
MRSA and in the percentage of enterococci resistant to
vancomycin isolated in acute care hospitals 18-20. ESBL-
producing pathogens are also a growing concern. Infection
with MRSA has been linked to prolonged hospitalisation,
increased morbidity, and even increased mortality 21-23.
Moreover, the additional costs associated with treating
infections caused by resistant pathogens can be immense.
One study conducted in 1995 found the attributable cost
of treating a patient with MRSA to be US$2,500 higher
than that of a patient with meticillin-sensitive S. aureus
(MSSA) 23.
Another study, designed to assess the effect of antimi-
crobial resistance on length of hospital stay, compared
infections due to four nosocomial pathogens (MRSA,
ESBL-producing K. pneumoniae, and carbapenem-resistant
Acinetobacter baumannii or Pseudomonas aeruginosa) 22,
and found a signiﬁcant increase in post-infection hospital
days associated with infections due to all four of
these resistant organisms. Patients infected with the
resistant Gram-negative isolates had prolonged hospital
stays of approximately 20 days compared to patients with
infections due to susceptible organisms 22.
Montravers et al. 11 looked at the outcomes for
100 patients who underwent surgery for post-operative
peritonitis, comparing outcomes for those who received
inappropriate initial empiric antimicrobial therapy with
outcomes for those whose initial empiric treatment was
deemed subsequently to be appropriate. The authors
found that therapy was generally inappropriate when the
organisms identiﬁed were pathogens such as P. aeruginosa,
ESBL-producing Enterobacteriaceae and MRSA.
Thus, the increased prevalence of these resistant
organisms must be borne in mind when physicians are
selecting appropriate antimicrobial therapy – the cost to
the patient in terms of potential increased morbidity and
mortality and the economic burden of such infections
cannot be overlooked.
Guidelines for antibiotic selection
Because intra-abdominal infections are nearly always
polymicrobial in nature, standard antimicrobial regimens
generally include combination therapy with an aminogly-
coside plus an anti-anaerobic agent (e.g., metronidazole
or clindamycin), or monotherapy with an agent that has
a broad spectrum of activity including activity against
anaerobes (e.g., imipenem–cilastatin). The Infectious
Disease Society of America (IDSA) published new guide-
lines for the treatment of complicated intra-abdominal
infections in September 2003 24. These guidelines offer
suggestions for the management of both community-
acquired and healthcare-associated post-operative noso-
comial infections. Because nosocomial infections are
caused by more-resistant ﬂora, including P. aeruginosa,
Enterobacter species, Proteus species, meticillin-resistant
Staphylococcus aureus, enterococci, and Candida species,
complex multi-drug regimens are recommended (e.g.,
an aminoglycoside or quinolone or a carbapenem and
vancomycin). Local nosocomial resistance patterns should
dictate empirical treatment, and treatment should be
altered on the basis of the results of a thorough
microbiologic workup 24.
The Surgical Infection Society (SIS) has also issued
guidelines regarding the various antibiotics that may be
used to treat intra-abdominal infections 25. Monotherapy
options recommended by these guidelines for treating
high-risk patients with nosocomial infections include the
carbapenems (meropenem and imipenem–cilastatin) or a
broad-spectrum penicillin combined with a b-lactamase
inhibitor (piperacillin–tazobactam) (Fig. 1). Combination
therapy with an amyinoglycoside is still a source of
debate 12. Meropenem and imipenem–cilastatin have ex-
tremely broad spectra of activity, making them suitable for
the empiric treatment of nosocomial bacterial infections.
It should be noted however, that imipenem–cilastatin is
contraindicated in patients with known hypersensitivity to
b-lactamase agents, and has been shown to cause seizures
in some patients. It should therefore be administered with
caution to patients with pre-existing CNS disorders. These
broad-spectrum agents only cover Gram-negative rods and
sensitive Gram-positives. Combination with vancomycin
is mandatory in severe post-operative infections for
MRSA, VRE or b-lactam-resistant enterococci. Furthermore,
Candida species are often involved in these infections and
need to be treated 26,27.
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Main Treatment
±
Piperacillin–tazobactam
Imipenem
Meropenem
Cefepime + metronidazole
Ceftazidime + metronidazole
Ciprofloxacin + metronidazole
Amikacin
or
Vancomycin
Figure 1. Antimicrobial therapeutic options for the treatment
of high-risk patients with nosocomial intra-abdominal infec-
tions. Adapted from refs. 24,25.
The development of newer antimicrobial agents for the
treatment of patients with post-operative or hospital-
acquired infections is important, given the rapid coloni-
sation of hospitalised patients with resistant pathogens.
Improved antimicrobial regimens for these higher-risk
patients would not only beneﬁt the patients themselves,
but could help limit the spread of drug-resistant
microorganisms.
New therapeutic options
Most antimicrobial agents currently approved and recom-
mended for the treatment of intra-abdominal infections
have little or no useful activity against MRSA and some
species of enterococci, such as Enterococcus faecium.
New therapeutic options must address this shortcoming.
Tigecycline is a novel, ﬁrst-in-class, glycylcycline that
shows promise in this regard. Tigecycline has a broad
spectrum of antibacterial activity against organisms
commonly encountered in intra-abdominal infections,
including aerobic and facultative Gram-positive and
Gram-negative bacteria and anaerobic bacteria 28-31. It
also provides in vitro activity against antibiotic-resistant
bacteria such as MRSA, VRSA, VRE and ESBL-producing
Enterobacteriaceae 32.
Clinical studies have compared tigecycline with imipenem–
cilastatin for the treatment of intra-abdominal infection 33.
Patients received either tigecycline (initial dose of
100mg, followed by 50mg intravenously every 12 h) or
imipenem–cilastatin (500/500mg intravenously every 6 h)
for 5–14 days. The primary diagnoses were: complicated
appendicitis (49.6%), complicated cholecystitis (13.9%),
intra-abdominal abscess (9.9%), perforation of intes-
tine (9.9%), complicated diverticulitis (6.9%), gastric/
duodenal perforations (5.4%) and peritonitis (3.4%). The
clinical responses at test-of-cure (12–44 days after
therapy) for the microbiologically evaluable patients were
86.1% (441/512) for tigecycline and 86.2% (442/513)
for imipenem–cilastatin (95%CI: –4.5% to 4.4%; p < 0.0001
for noninferiority). Corresponding clinical cure rates for
the microbiologically-modiﬁed intent-to-treat (m-mITT)
populations were 80.2% (506/631) for tigecycline vs 81.5%
(514/631) for imipenem/cilastatin (95%CI: –5.8% to 3.2%;
p < 0.0001 for noninferiority). Eradication of intra-
abdominal isolates mirrored the clinical cure rates:
86.1% and 86.2%, respectively. At test-of-cure (TOC)
visit eradication rates were: E. coli, 86.2% and 87.1%;
K. pneumoniae, 88.5% and 90.0%; meticillin-susceptible
S. aureus 92.9% and 91.7%, respectively. Bacterial
eradication for patients with MRSA was 75% (3/4) for
tigecycline compared with 33% (1/3) for imipenem–
cilastatin. Both treatment groups produced similar safety
and tolerability proﬁles, with the most commonly reported
adverse events for tigecycline and imipenem–cilastatin
being nausea (24.4% and 19.0%; p = 0.010), vomiting (19.2%
and 14.3%; p = 0.008) and diarrhoea (13.8% and 13.2%;
p = 0.719). The incidence of post-operative infections was
very low in both groups 33.
The ﬂuoroquinolone moxiﬂoxacin has also recently
received approval for use in complicated intra-abdominal
infections. In a recently published study patients were
randomised to receive either IV/PO moxiﬂoxacin (400mg
q24 hours) or comparator (IV piperacillin–tazobactam
[3.0/0.375 g q6 hours] +/– PO amoxicillin–clavulanate
[800/114mg q12 hours]), 5–14 days 34. The primary
diagnoses were: complicated appendicitis (78.9%), pe-
foration of large or small bowel (17.5%), ileocolic
abscess (7.2%), gastric/duodenal perforation (5.9%), post-
operative upper/lower gastrointestinal infection (13.53%).
Seventeen patients had other infections: 5 cholecystitis,
6 intra-abdominal abscess and 6 miscellaneous upper
gastrointestinal infections. Clinical cure rates at TOC
were similar between the two groups: 80% (146/183)
for moxiﬂoxacin and 78.1% (153/196) for comparator
(95%CI: –7.4% to 9.3%). For patients with hospital-acquired
infection, moxiﬂoxacin achieved a signiﬁcantly higher cure
rate (82%, 22/27) than the comparator (55%, 17/31)
[p = 0.05]. Bacteriologic success rates were 78% (117/150)
and 77% (126/163), respectively. The incidence of adverse
events was similar in the two arms of the study, with
the most common adverse events for moxiﬂoxacin and
comparator being nausea (17.3% and 11.3%), hypokalemia
(12.1% and 11.9%), constipation (13.3% and 10.1%) and
abdominal pain (10.9% and 12.8%, respectively). These
results are consistent with other recommended treatment
regimens. Further studies comparing ﬂuoroquinolones
with or without metronidazole are needed. A pooled
analysis designed to assess the efﬁcacy of moxiﬂoxacin
against anaerobic bacteria in complicated intra-abdominal
infections (cIAI) was recently presented. This showed that
monotherapy with moxiﬂoxacin 400mg once daily provided
clinical and bacteriological success rates against anaerobic
pathogens comparable to combination therapy with either
piperacillin–tazobactam or ceftriaxone–metronidazole in
patients with cIAI. Overall, the combined cure rates were
80.4% (345/429) for patients treated with moxiﬂoxacin and
80.4% (371/461) for patients in the combination therapy
treatment arms 35. However, the spectrum of moxiﬂoxacin
is more suited to community-acquired infections than
nosocomial infection because of a lack of activity against
multidrug-resistant pathogens such as ESBL, MRSA and
VRE.
Summary
The selection of antimicrobial therapy for nosocomial
intra-abdominal infections requires careful consideration
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of several factors, including the patient’s history, par-
ticularly prior antibiotic exposure and comorbidities, as
well as local resistance patterns of potential nosocomial
pathogens. Failure to use early, appropriate antimicrobial
therapy in patients with nosocomial intra-abdominal
infections can have a major impact on mortality, the need
for further surgery, length of hospital stay, selection of
resistant strains, and overall healthcare costs. Current
guidelines recommend the selection of an agent or agents
that cover both aerobic and anaerobic organisms.
Tigecycline, the ﬁrst of the glycylcycline class of an-
tibacterial agents, has excellent activity against antibiotic-
susceptible as well as -resistant Gram-positive organisms
and against key Gram-negative facultative bacteria
commonly associated with intra-abdominal infections,
whatever their resistance pattern. Clinical experience
to date has shown it to be safe and effective in
the treatment of complicated intra-abdominal infections.
Accordingly, tigecycline represents a promising addition
to the current therapeutic options for the treatment
of these serious infections. Moxiﬂoxacin is the only
marketed ﬂuoroquinolone antibiotic approved by the U.S.
Food and Drug Administration (FDA) as monotherapy to
treat complicated intra-abdominal infections. However,
moxiﬂoxacin may represent an opportunity in community-
acquired infections, not in nosocomial infections due to
its spectrum. A number of other new agents are in
development and may result in a revision in clinical
practice guidelines as more data become available.
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